LA JOLLA, Calif.--Digital Gene Technologies, a total gene expression and comparison company here, announced that it has appointed Andrew Schwab as vice-president of business development to coordinate the company's business development activities and institutional investor relations.
Schwab came from the investbanking firm NationsBanc Montgomery Securities, where he was vice-president of the firm's health care group.
Cellomics Receives $1 Million Grant From National Cancer Institute PITTSBURGH--Cellomics, a privately held company founded here in 1996, received a component of a five year $4.2 million program project grant from the National Cancer Institute Special Emphasis Panel, the company announced. Cellomics' project, entitled Combinatorial Approaches for Novel Anticancer Agents, will receive approximately $1 million of the grant. Led by John Lazo, chairman of the University of Pittsburgh School of Medicine pharmacology department and a member of the Cellomics scientific advisory board, the project's goal is to generate novel chemical libraries based on potent, natural product-derived pharmacophores and to identify promising new lead structures that affect cancer relevant molecular targets.
Cellomics will design and implement high-content screening approaches to screen the combinatorial libraries of anticancer drugs that will be synthesized throughout the program project. Molecular and synthetic fluorescent reagents will be employed in high-content screening of a variety of potential targets. Cellomics' ArrayScan System will serve as the platform for both the fixed and live cell assays designed to screen the combinatorial libraries of anticancer lead compounds.